[High-dose Ara-C treatment of acute leukemia].

Abstract

High-dose cytosine arobinoside (HDAra-C) was originally introduced in clinical hematology for the treatment of refractory or relapsed acute leukemia. Recently, however, this treatment has been tried for remission induction and/or consolidation in early leukemia cases, and resulted in a fairly percentage of long-term survival cases. HDAra-C in combination with anthracyclines is now considered to be a treatment which may afford some hope of a cure in a certain percentage of cases of adult acute non-lymphocytic leukemia. This treatment also has the advantage of being an effective treatment for meningeal leukemia, since a high concentration of Ara-C effective enough to kill leukemic cells is maintained in the cerebrospinal fluid after intravenous infusion of high-dose Ara-C. In this paper, the HDAra-C treatment of acute leukemia is reviewed and the results of our group study on the treatment of 30 cases of refractory acute leukemia with HDAra-C are discussed.

• Authors: F Takaku
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 5 Pg. 1823-8 (May 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3707145 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Cytarabine

Topics

• Acute Disease
• Antineoplastic Agents (pharmacology)
• Cytarabine (administration & dosage, therapeutic use)
• Drug Resistance
• Humans
• Leukemia (drug therapy, mortality)